A Randomized Phase 3 Study Comparing <scp>P2B001</scp> to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early Parkinson's DiseaseC. Warren Olanow, Lawrence Elmer, David Kreitzman et al.|Movement Disorders|2023Cited by 5